IR700 Nanocomposition Targeted Photodynamic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a long-standing need for innovative drugs and medical products, particularly in cardiology, oncology, dermatology, and bariatrics, to effectively diagnose and treat conditions and diseases in animals and humans, where existing solutions are inadequate.
Innovation Solution
Development of nanocompositions comprising a photosensitizer, such as a phthalocyanine dye, a nanoparticle like 8PEG, and a targeting agent, specifically designed for photodynamic therapy to target cardiac, oncologic, bariatric, or dermatologic conditions, where the nanocomposition is configured to accumulate in targeted tissues and be activated by light to produce reactive oxygen species.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional photosensitizers are used in photodynamic therapy, then therapeutic effect is achieved, but non-specific distribution to healthy tissues occurs causing unwanted side effects
Solution Approach 1:
The photosensitizer is segmented from the delivery system by using a nanoparticle platform. The PS is loaded onto the nanoparticle surface or encapsulated within it, allowing the nanoparticle to serve as a separate delivery vehicle that can be functionalized independently with targeting moieties while carrying the therapeutic payload.
Solution Approach 2:
The nanoparticle acts as an intermediary between the photosensitizer and the target tissue. It serves as a carrier that facilitates specific delivery to diseased tissues through surface-functionalized targeting agents, while the PS itself remains protected and controlled until activation at the target site.
2Reliability
If high concentrations of photosensitizer are used to improve therapeutic effect, then treatment efficacy increases, but phototoxicity to surrounding healthy tissues increases
Solution Approach 1:
The nanoparticle enables local concentration of the photosensitizer at the disease site through targeted delivery. The PS is delivered specifically to the tumor or affected tissue via surface-functionalized targeting agents, creating a localized high concentration where it is needed while maintaining low systemic concentrations that minimize off-target phototoxicity.
Solution Approach 2:
The invention changes the distribution parameters of the photosensitizer from systemic to localized. By controlling the nanoparticle's biodistribution, cellular uptake, and retention properties, the PS concentration is optimized locally at the target site while systemic exposure is minimized, altering the concentration-time profile to favor therapeutic efficacy over toxicity.
3Area of stationary object
If systemic administration of photosensitizer is used, then broad tissue coverage is achieved, but accumulation in non-target organs occurs reducing treatment specificity
Solution Approach 1:
The nanoparticle platform provides multi-functionality by combining drug delivery, targeting, and imaging capabilities in a single system. The nanoparticle can be administered systemically to achieve broad tissue distribution, while surface-functionalized targeting agents guide it specifically to diseased tissues, and imaging agents enable real-time tracking of its location and accumulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanocompositions provide targeted and effective photodynamic therapy with minimal temperature increase, avoiding thermal damage, and specifically target affected tissues, offering a promising solution for various medical conditions.
Implementation Method 1
a method for ablating, (e.g., killing, destroying, rendering inert), biological tissue by photo-oxidation utilizing photosensitizer ("PS") molecules. When the photosensitizer is exposed to a specific wavelength or wavelengths of light, it produces a form of oxygen from adjacent (e.g., in situ, local, intercellular, intracellular) oxygen sources, that kills nearby cells
Implementation Method 2
The terms "passive targeting" and "PT" and similar such terms, unless expressly stated otherwise, should be given their broadest possible meaning, and would include accumulation of a nanoparticle in a targeted tissue by a non-specific mechanism, e.g., the enhanced permeability and retention ("EPR") effect
Implementation Method 3
the enhanced permeability and retention ("EPR") effect
Implementation Method 4
The terms "active targeting" and "AT" and similar such terms, unless expressly stated otherwise, should be given their broadest possible meaning, and would include specific binding of a nanoparticle to a targeted tissue by a specific mechanism, e.g., by a targeting agent ("TA")
Data Source
AI summary
A nanocomposition for use in treating cardiac, oncologic, bariatric, or dermatologic indications, conditions and diseases condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a RGD, or iRGD targeting agent. Administering a product comprising IR700 to a patient, whereby the IR700 is delivered to the target tissue, and found in only target tissue; and administering light to activate the IR700, thereby producing an ROS.